Nabumetone

Introduction Overview

Generic Name

Nabumetone

Brand Name

Relafen, Relafen DS

Dosage Form

Oral tablet (1000 mg; 500 mg; 750 mg)

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Nabumetone is an orally administered NSAID that is rapidly absorbed following ingestion. The drug itself is a prodrug and undergoes hepatic biotransformation to its active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA), which is responsible for the anti-inflammatory effects. The absorption phase occurs primarily in the gastrointestinal tract, with good bioavailability. Peak plasma concentrations of 6-MNA typically occur 2 to 4 hours post administration. Food does not significantly affect the extent of absorption, allowing flexibility in dosing with or without meals. The oral bioavailability is adequate to achieve therapeutic plasma levels at standard dosing.

Distribution:
Nabumetone’s active metabolite 6-MNA is highly protein bound, predominantly to albumin, with binding levels exceeding 98%. The high plasma protein binding limits distribution to tissues but ensures a stable concentration in plasma. Volume of distribution is moderate, reflecting limited extravascular penetration. The drug and its metabolites are distributed into synovial fluid, achieving concentrations sufficient to exert anti-inflammatory action at target sites such as joints. The distribution into synovial fluid is clinically important for its use in arthritis treatment. Nabumetone does not readily cross the blood-brain barrier, minimizing central nervous system exposure.

Metabolism:
Nabumetone is extensively metabolized in the liver via microsomal oxidation. It is a non-acidic prodrug that undergoes biotransformation primarily via cytochrome P450 enzymes, notably CYP1A2, to its active acid metabolite 6-MNA. Further phase II metabolism includes glucuronidation of 6-MNA, facilitating renal elimination. The metabolism is subject to hepatic function status, and impairment can alter pharmacokinetics, necessitating careful monitoring. No active metabolites beyond 6-MNA are clinically significant. The metabolic pathways avoid formation of toxic metabolites, contributing to its relatively favorable gastrointestinal tolerability compared to other NSAIDs.

Elimination:
The elimination of nabumetone is primarily through renal excretion of metabolites. About 90% of the drug is eliminated in urine predominantly as glucuronide conjugates of 6-MNA. Fecal elimination accounts for a minor portion. The elimination half-life of the active metabolite 6-MNA ranges from 20 to 25 hours, allowing once or twice daily dosing. Renal impairment can reduce clearance, thereby increasing plasma concentrations and risk of toxicity. Dose adjustments may be required in patients with compromised renal function. There is minimal excretion of unchanged nabumetone in urine, underscoring its prodrug status. Nabumetone does not undergo significant enterohepatic recirculation.

Dosage Forms

Available Dosage Forms:
Nabumetone is available exclusively as oral tablets in multiple strengths designed to provide flexibility in dosing. The commercial formulations include:
- Oral tablet 500 mg
- Oral tablet 750 mg
- Oral tablet 1000 mg
These formulations allow for tailored dosage adjustments based on clinical response, weight, and patient tolerance.

Dosages for Adults and Adolescents:
For osteoarthritis and rheumatoid arthritis in adults and adolescents 18 years and older, the recommended initial dose is 1000 mg once daily orally. Maintenance therapy generally involves titrating dose between 1500 mg to 2000 mg daily, administered as a single dose or divided into two doses (e.g., 500 mg twice daily or 1000 mg twice daily). The maximum recommended daily dose is 2000 mg. Patients weighing less than 50 kg may require lower dosages, often not exceeding 1000 mg daily. Dose adjustments should aim for the minimal effective dose for the shortest feasible duration to decrease risk of adverse effects.

Specific Patient Populations:
Elderly patients may be more sensitive to the adverse effects of nabumetone, particularly risk of gastrointestinal bleeding and renal toxicity, necessitating cautious dosing and close monitoring. In patients with mild to moderate hepatic or renal impairment, dosage reductions and monitoring of function are advised to mitigate accumulation. Nabumetone is not approved for pediatric use under 18 years of age. Pregnant patients should avoid use, especially in the third trimester, due to risks of fetal renal impairment and premature closure of the ductus arteriosus. Breastfeeding is not recommended while on nabumetone as the drug may pass into breast milk. No specific liquid or injectable formulations of nabumetone exist, limiting administration routes to oral tablets.

Mechanism Of Action

Nabumetone is a nonsteroidal anti-inflammatory drug (NSAID) that functions predominantly through inhibition of prostaglandin synthesis, a key mediator of inflammation and pain. As a prodrug, nabumetone itself is inactive until hepatic metabolism converts it to its active metabolite 6-methoxy-2-naphthylacetic acid (6-MNA). This active metabolite selectively and reversibly inhibits cyclooxygenase (COX) enzymes, primarily COX-2, although some COX-1 inhibition occurs. This inhibition decreases the conversion of arachidonic acid into prostaglandins, which are responsible for pain, inflammation, and fever.

On a cellular level, nabumetone’s active metabolite blocks COX enzymes within inflammatory cells such as macrophages and synoviocytes. This action reduces prostaglandin-mediated vasodilation and vascular permeability, thereby decreasing edema and pain sensitization. By limiting prostaglandin E2 synthesis, nabumetone modulates nociceptive pathways, diminishing peripheral and central sensitization to painful stimuli. Furthermore, the anti-inflammatory effects reduce joint swelling and stiffness characteristic of rheumatoid and osteoarthritis.

Biochemically, nabumetone exhibits a comparatively selective affinity for COX-2 over COX-1 relative to many other NSAIDs, conferring some gastrointestinal tolerability advantages by sparing COX-1 mediated gastric mucosal protection. This selectivity is supported by clinical studies demonstrating less frequent gastrointestinal side effects than nonselective NSAIDs. Clinically, these properties translate to effective symptom relief in arthritis with a potentially decreased risk of ulceration or bleeding.

Comparatively, nabumetone differs mechanistically from acidic NSAIDs such as ibuprofen and naproxen by virtue of its prodrug status and selectivity profile. Its active metabolite’s slower onset but prolonged half-life allows for once or twice daily dosing. Research evidence demonstrates nabumetone’s efficacy and safety profile supports its use in chronic inflammatory diseases, with ongoing trials evaluating cardiovascular safety and renal outcomes compared to newer NSAIDs.

Pharmacological Actions

Inhibition of cyclooxygenase enzymes, reducing prostaglandin synthesis.
Anti-inflammatory effects via decreased production of pro-inflammatory mediators.
Analgesic properties by diminishing peripheral and central pain sensitization.
Antipyretic activity through lowering of hypothalamic prostaglandin production.
Selective COX-2 inhibition resulting in moderate gastrointestinal safety profile.
Reduction of joint inflammation and swelling in arthritis conditions.
Prodrug conversion to active metabolite 6-MNA enabling sustained therapeutic effect.
Moderate protein binding facilitating steady plasma concentrations.
Decreased platelet aggregation compared to nonselective NSAIDs, with minimal effect on hemostasis.
Prolonged half-life supporting convenient once or twice daily dosing.
Minimal central nervous system penetration limiting CNS adverse effects.
Lack of significant active metabolites reduces risk of toxic accumulation.
Renal effects due to prostaglandin inhibition that can impact renal blood flow.
Potential to exacerbate fluid retention via renal prostaglandin modulation.
Compatibility with other anti-inflammatory agents needs cautious consideration due to additive toxicity.

Therapeutic Or Clinical Uses

Relief of signs and symptoms of osteoarthritis.
Management of rheumatoid arthritis inflammation and pain.
Reduction of joint stiffness and swelling associated with chronic arthritis.
Alleviation of mild to moderate musculoskeletal pain related to inflammatory conditions.
Treatment of arthritis-related functional limitations and improving mobility.
Symptomatic relief in degenerative joint diseases.
Off-label use for other inflammatory conditions as determined by physician discretion.
Alternative NSAID in patients intolerant to acidic NSAIDs due to gastrointestinal sensitivity.
Chronic management of inflammation in autoimmune-mediated joint diseases.
Use in patients requiring long-term NSAID therapy with monitored risk-benefit assessment.
Supportive management of inflammation in soft tissue injuries related to arthritis.
Reducing inflammatory biomarkers and cytokines in joint tissues.
Adjunct therapy in multimodal pain management in arthritis patients.
Improvement in quality of life indices in chronic arthritis sufferers.
Prevention of progression of arthritis symptoms through long-term control of inflammation.

Side Or Adverse Effects

Gastrointestinal discomfort including stomach pain, indigestion, nausea.
Diarrhea, constipation, and flatulence due to gastrointestinal irritation.
Peripheral edema presenting as swelling in the hands and feet.
Headache and dizziness, which may affect balance and alertness.
Skin reactions such as itching and rash indicating hypersensitivity.
Tinnitus or ringing in the ears, a possible sign of NSAID toxicity.
Serious allergic reactions including hives, wheezing, and facial swelling.
Gastrointestinal bleeding evidenced by bloody or tarry stools or vomiting blood.
Signs of liver impairment such as jaundice, dark urine, and flu-like symptoms.
Renal toxicity presenting with reduced urine output, swelling, or electrolyte imbalances.
Anemia manifesting as pale skin, fatigue, and shortness of breath.
Increased risk of cardiovascular events such as heart attack and stroke.
Potential for severe skin reactions with blistering and peeling.
Fluid retention causing rapid weight gain and exacerbation of hypertension.
Central nervous system disturbances including light-headedness and fatigue.

Precautions

Use the lowest effective dose for the shortest duration to reduce adverse risks.
Inform physician of any history of cardiovascular disease, hypertension, or stroke.
Monitor renal and hepatic function during prolonged therapy.
Exercise caution in patients with pre-existing gastrointestinal disorders including ulcers.
Avoid concurrent use with other NSAIDs or anticoagulants unless medically supervised.
Avoid alcohol due to increased risk of gastrointestinal bleeding.
Pregnant women, especially during the third trimester, should avoid nabumetone.
Not recommended for pediatric patients under 18 years of age.
Patients with asthma or NSAID-sensitive respiratory conditions should avoid this medication.
Report any signs of skin rash or hypersensitivity immediately.
Use protective measures against UV exposure due to increased photosensitivity.
Regularly evaluate blood pressure in patients with hypertension on nabumetone.
Adjust dose or discontinue in case of fluid retention or worsening heart failure.
Be wary of drug interactions with lithium, methotrexate, and warfarin.
Keep medication out of reach of children and do not share with other individuals.

Warnings

Nabumetone increases the risk of fatal heart attack or stroke, especially with prolonged use.
Avoid use immediately before or after coronary artery bypass graft (CABG) surgery.
May cause fatal gastrointestinal bleeding or perforation without warning symptoms.
Older adults have a higher risk of gastrointestinal, cardiovascular, and renal adverse events.
Monitor for signs of liver dysfunction including jaundice and dark urine.
Use with caution in patients with congestive heart failure or fluid retention.
Concomitant use with anticoagulants or antiplatelet agents increases bleeding risk.
Discontinue immediately if severe skin reactions or allergic reactions are observed.
Avoid breastfeeding during therapy due to potential drug transmission through milk.
Avoid in patients with known hypersensitivity to nabumetone, aspirin, or other NSAIDs.
May impair renal function leading to acute kidney injury in susceptible individuals.
Long-term use may increase the risk of hypertension and exacerbate pre-existing conditions.
Do not exceed recommended dosages to prevent serious toxicity and adverse effects.
NSAID use in late pregnancy may cause premature closure of the fetal ductus arteriosus.
Use with caution in patients with a history of peptic ulcer disease or gastrointestinal bleeding.

Contraindication

Known hypersensitivity or allergy to nabumetone or any component of the formulation.
History of aspirin or NSAID-induced asthma, urticaria, or acute allergic reactions.
Active peptic ulcer disease or gastrointestinal bleeding.
Severe heart failure or uncontrolled hypertension.
Patients immediately before or after coronary artery bypass graft (CABG) surgery.
Severe hepatic impairment or active liver disease.
Severe renal impairment or patients on dialysis.
Pregnancy in the third trimester due to risk of fetal harm.
Breastfeeding mothers due to lack of safety data.
Pediatric patients under 18 years old; safety and efficacy not established.
Known bleeding disorders or coagulopathies.
Concomitant use with other non-selective NSAIDs or high-dose aspirin.
Patients with history of serious skin reactions to NSAIDs.
Hypovolemia or dehydration increasing risk of renal toxicity.
Patients with uncontrolled asthma exacerbated by NSAIDs.

Drug Interactions

Concurrent use with anticoagulants such as warfarin increases bleeding risk.
Additive nephrotoxicity when combined with diuretics, ACE inhibitors, or ARBs.
Methotrexate clearance may be reduced, increasing toxicity risk.
Lithium serum levels may be elevated due to decreased renal clearance.
Corticosteroids increase risk of gastrointestinal ulceration and bleeding.
Concomitant use with SSRIs or other antidepressants may increase bleeding tendency.
Avoid combining with other NSAIDs or salicylates to prevent additive toxicity.
May interfere with antihypertensive efficacy of beta-blockers and ACE inhibitors.
Potentiation of nephrotoxic effects with cyclosporine.
Interactions with alcohol can enhance gastrointestinal side effects and bleeding.
Potential interaction with diuretics causing reduced diuretic efficacy and renal effects.
NSAIDs may reduce platelet aggregation and increase bleeding when combined with antiplatelet agents.
Possible reduced renal elimination of digoxin with concomitant NSAID use.
Probenecid may increase plasma concentrations of nabumetone by inhibiting renal excretion.
Careful monitoring needed when combined with drugs that affect coagulation or platelet function.

Preparations Of The Drug

Relafen oral tablets available in 500 mg strength.
Relafen oral tablets available in 750 mg strength.
Relafen oral tablets available in 1000 mg strength.
No liquid or injectable preparations currently available.
Tablets designed for oral use with standard bioavailability.
Commercial packaging in blister packs or bottles depending on market requirements.
No controlled-release formulations currently approved.
Available as branded formulations under several brand names including Relafen and Relafen DS.
Supplied with medication guides detailing dosage and safety information.
Storage recommended at room temperature away from moisture and heat.
Tablets coated to improve swallowing and minimize gastrointestinal irritation.
Formulations comply with pharmacopeial standards for quality and potency.
Not formulated with additional active ingredients; monotherapy dosage form.
Packaging designed to safeguard from light and moisture to maintain stability.
Typical shelf life ranges from 2 to 3 years from manufacturing date under recommended conditions.